Safety Update on Erythropoiesis-Stimulating Agents: Trials Within and Outside the Accepted Indications
|
|
- Hollie Barker
- 5 years ago
- Views:
Transcription
1 Safety Update on Erythropoiesis-Stimulating Agents: Trials Within and Outside the Accepted Indications Pere Gascón Medical Oncology, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain Key Words. Erythropoiesis-stimulating agents ESAs Anemia Safety Survival Disclosure: The author has received honoraria for lecturing from Roche Pharma, Amgen, and Janssen-Cilag, manufacturers of epoetin beta, darbepoetin alfa, and epoetin alfa, respectively. No other potential conflicts of interest were reported by the author, planners, reviewers, or staff managers of this article. Introduction Cancer patients undergoing chemotherapy frequently experience anemia [1]. In the era before the development of erythropoiesis-stimulating agents (ESAs), RBC transfusion was the main management option. Erythropoietic agents currently used for the treatment of chemotherapy-induced anemia include: epoetin alfa (Eprex /Epypo, Ortho Biotech/Janssen-Cilag, High Wycombe, United Kingdom; Procrit, Ortho Biotech Products, L.P., Bridgewater, NJ), epoetin beta (NeoRecormon, Hoffmann-La Roche, Basel, Switzerland), and darbepoetin alfa (Aranesp, Amgen Inc., Thousand Oaks, CA). Since the introduction of ESAs, many patients have benefited from their ability to reliably raise hemoglobin (Hb) levels without the need for transfusion, and to improve quality of life [2 4]. Recently, however, there has been concern that the use of ESAs might actually be reducing overall survival in cancer patients (Table 1) [3, 5 11]. This has prompted regulatory authorities such as the Oncology Drug Advisory Committee of the U.S. Food and Correspondence: Pere Gascón, M.D., Ph.D., Hospital Clinic, Division of Medical Oncology, IDIBAPS, Institut Clinic Malalties Hemato- Oncològiques (ICMHO), University of Barcelona, Barcelona, Spain. Telephone: ; Fax: ; gascon@clinic.ub.es Received November 16, 2007; accepted for publication January 7, AlphaMed Press /2008/$30.00/0 doi: /theoncologist.13-S3-4 The Oncologist 2008;13(suppl 3): Abstract Certain studies in which erythropoiesis-stimulating agents (ESAs) have been given not with the aim of correcting anemia but to achieve higher target levels of hemoglobin have shown significantly poorer survival among treated patients. However, studies in which ESAs were administered with the aim of reducing the need for RBC transfusions in patients with chemotherapyassociated anemia demonstrate that the use of these agents is not associated with any adverse effect on survival when compared with placebo controls. We can therefore be reassured that using ESAs within the labeled indications will not adversely affect patient outcome. The Oncologist 2008;13(suppl 3):4 10 Drug Administration and the European Medicines Evaluation Agency urgently to review the available data [12]. In doing so, one important distinction that must be made is between studies that have administered ESAs within their currently accepted indications and those that have investigated the potential risks and benefits of extending their use to wider patient groups. Use according to the label means essentially confining eligibility to patients with chemotherapy-induced anemia, starting treatment only if the baseline Hb level is <11 g/dl, and discontinuing treatment when the Hb level rises to >12 g/dl in the U.S. and keeping Hb levels in the range of g/dl in Europe. Overview of Epoetin Studies Figure 1 shows the hazard ratio (HR) for survival in 12 randomized, double-blinded, placebo-controlled studies of epoetin alfa [2, 3, 7, 12 21]. Values to the left of the central line favor the ESA, values to the right favor placebo. The width of the horizontal bars, on either side of the HR, indicates the 95% confidence interval (CI) around the esti-
2 Gascón 5 Table 1. Overview of meta-analyses of erythropoiesis-stimulating agents (ESAs): Survival Description (No. studies and patients) CT-induced anemia extended analysis set (22; 4,536 patients) 'Cochrane-like' (epoetin alfa only) (35; 6,918 patients) Cochrane (42; 8,167 patients) Updated Cochrane (48; 9,652 patients) Definition of study set used All randomized, controlled, company studies All epoetin alfa studies All ESAs randomized, controlled All ESAs, randomized, controlled + 6 HR (95% CI) on study data 1.17 ( ) 1.17 ( ) 1.08 ( ) 1.03 ( ) HR (95% CI) inc. long-term FU data 1.04 ( ) 0.97 ( ) Abbreviations: CI, confidence interval; CT, chemotherapy; FU, follow-up; HR, hazard ratio; NA, not available. NA NA Figure 1. Meta-analysis on randomized, double-blinded, placebo-controlled studies that were conducted with epoetin alfa: epoetin alfa survival [2, 3, 12 21]. Adapted from Bohlius J, Wilson J, Seidenfeld J et al. Recombinant human erythropoietins and cancer patients: Updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006;98: , with permission. Abbreviations: BEST, Breast Cancer Erythropoietin Survival Trial; CI, confidence interval; ESA, erythropoiesis-stimulating agent; HR, hazard ratio.
3 6 Safety Update on ESAs mate. Ideally an HR of 1.00 shows no negative impact of ESAs on survival. The figure distinguishes between trials in which the use of epoetin alfa can be considered on-label and studies in which the agent was used for patients outside the accepted indications. The only trial that produced an HR that significantly favors placebo (HR, 1.36; 95% CI, ) is the Breast Cancer Erythropoietin Survival Trial (BEST) study [7, 21]. In that trial, the death rate at 1 year among placebo patients was 23.9% and that among patients receiving epoetin alfa was 30.6%. This excess mortality seemed attributable in part to a higher rate of venous thromboembolic events. Those entered into the study had metastatic breast cancer and were receiving first-line chemotherapy. The aim of the trial was to assess the effect on survival and quality of life of maintaining Hb in the range of g/dl. Patients could enter the study if their Hb level was 13 g/dl at baseline or during treatment, and the majority of the 939 women enrolled were nonanemic (the median Hb was 12.8 g/dl). Clearly, this study used epoetin alfa off-label. The HR for on-study mortality from these 12 studies of anemia was 1.13 (95% CI, ). However, this included one study conducted in patients not receiving chemotherapy (Study H87-032, H87-014, H87-015) and two studies (BEST, N93-004) in which treatment went beyond the correction of anemia. Restricting consideration to the nine studies that used epoetin alfa in the chemotherapy setting, and excluding the BEST data because of its off-label use, gives an HR for survival of 1.00 (95% CI, ). Hence, the effect of using this epoetin alfa for its licensed indication of treating chemotherapyinduced anemia appears to be entirely neutral with regard to mortality. Meta-Analyses of Mortality in Studies Using ESAs Figure 2 presents a similar plot, showing the odds ratio (OR) of death and the 95% CI for 36 individual randomized, controlled studies in which ESAs were administered to 9,652 patients [2, 3, 12 19, 21 46]. The figure again makes a distinction between the majority of studies, in which ESAs were used for on-label indications, and the minority (lower third of the list), in which the use was off-label. Meta-analysis of these data using either a fixed effects or a random effects model produces the same conclusion: the overall mortality risk associated with the ESAs is 1.03 (95% CI, ). These data therefore again support the view that the use of ESAs in general has no adverse effect on the risk for death. A previous Cochrane review reported an overall HR of 1.08 (95% CI, ) (Table 1) [3]. The HR for studies limiting entry to patients with an Hb level <10 g/dl was 1.01, and it was 0.98 for patients with an entry Hb of g/dl. The HR significantly favors placebo over ESA only in those studies having an eligibility criterion of >12 g/dl Hb at the start of therapy. In this setting, the HR of treatment is 1.27 (95% CI, ). Two previous meta-analyses, an extended analysis of trials of ESAs in chemotherapy-induced anemia and a Cochrane-like analysis including only epoetin trials, both arrived at an HR of 1.17 (Table 1). In both cases, the confidence interval spanned 1.00, and in both studies the inclusion of longer-term follow-up data suggested a lower HR. Off-Label Use of ESAs Recent attention has been focused particularly on five trials that have investigated the possible role of ESAs outside their labeled indications (Table 2) [5 7, 10, 21, 39, 47]. Of these trials, that of Aapro et al. [39], in metastatic breast cancer patients who were treated with no limit on Hb, reported an HR for epoetin versus placebo of 1.07 [39]. However, as already noted, the HR for mortality of 1.37 found by Leyland-Jones et al. [7], again in metastatic breast cancer, was statistically significant. Importantly, the majority of women in that trial did not meet a conventional definition of anemia. That was true also of the Erythropoietin in Head and Neck Cancer (ENHANCE) study, in which Henke et al. [5] randomized head and neck cancer patients undergoing radiation therapy to an ESA, in the hope of achieving radiosensitization. In that study, the relative risk for death was It was even higher (1.84) in Wright et al. s [48] smaller study of patients with small-cell lung cancer. However, in that trial as well, the Hb value set for inclusion ( 14.5 g/dl) was again set high. In the Amgen study, reporting an HR of 1.22, darbepoetin was given in the nonchemotherapy (non- CT) setting of palliation in progressive disease. The Kaplan Meier survival curves for the BEST, ENHANCE, Amgen non-ct, and Breast Cancer Anemia and the Value of Erythropoietin (BRAVE) studies are shown in Figure 3 [5 7, 10, 21, 39, 47]. In the BEST and ENHANCE studies, the survival rates were lower for patients receiving epoetin than for those receiving placebo. In the BEST, ENHANCE, and BRAVE studies, patients were treated with epoetin beyond the approved Hb target levels [5 7, 21, 39]. The Oncologist Conclusions Overall, therefore, the impression given by these data is reassuring. The use of ESAs in off-label indications cannot be encouraged, and they should be used only within the context of a clinical trial. However, patients with chemo-
4 Gascón 7 Figure 2. Meta-analysis of death for erythropoiesis-stimulating agent (ESA) studies: 39 studies, 9,652 patients; OR, 1.03; 95% CI, [2, 3, 12 19, 21 46]. Meta-analysis using log OR, I 2 = 0. Sensitivity analysis excluding Razzouk, O Shaughnessy, Wilkinson, and INT-47 has a random effects model OR of 1.02 (95% CI, ). Three studies did not report any deaths (Hedenus et al. [30], Cascinu et al. [49], Kurz et al. [50]) but were randomized cancer-induced anemia studies. Adapted from Bohlius J, Wilson J, Seidenfeld J et al. Recombinant human erythropoietins and cancer patients: Updated metaanalysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006;98: , with permission of Oxford University Press. Abbreviations: CI, confidence interval; HR, hazard ratio; OR, odds ratio. Table 2. Off-label erythropoiesis-stimulating agent (ESA) studies [5 7, 10, 21, 39,47] Study (author) BEST (Leyland-Jones) ENHANCE (Henke) EPO-CAN-15 (Wright) Amgen non-ct 103/149 No. patients (ESA/PBO) How outside label Stage 3+4 (E/P; %) 448/456 No Hb limit All metastatic 121/121 High Hb goal RT (non-ct) Tumor type Breast 96% / 99% Head & neck Survival and outcome reasons HR: 1.37 (12 mo) HR: 1.00 (ext) VTEs RR: 1.39 Over-treatment Imbalance in risk factors 52/52 No Hb limit SCLC HR: /444 Non-CT 82.5% / 80.6% BRAVE (Aapro) 231/232 No Hb limit All metastatic Mixed HR: 1.22 Progressive, palliative patients Breast HR: 1.07 Abbreviations: BEST, Breast Cancer Erythropoietin Survival Trial; BRAVE, Breast Cancer Anemia and the Value of Erythropoietin; CT, chemotherapy; E/P, epoietin/placebo; ENHANCE, Erythropoietin in Head and Neck Cancer; EPO-CAN-15, Epoietin-Canadian study-15; Hb, hemoglobin; HR, hazard ratio; PBO, placebo; RR, relative risk; RT, radiotherapy; SCLC, small cell lung cancer; VTE, venous thromboembolism.
5 8 Safety Update on ESAs Figure 3. Off-label erythropoiesis-stimulating agent (ESA) studies: Summary of the BEST, ENHANCE, Darbepoetin alfa non- CT, and BRAVE studies survival results. Based on data from [5 7, 10, 21, 39, 47]. Abbreviations: BEST, Breast Cancer Erythropoietin Survival Trial; BRAVE, Breast Cancer Anemia and the Value of Erythropoietin; CI, confidence interval; CT, chemotherapy; Erythropoietin in Head and Neck Cancer; HR, hazard ratio. therapy-related anemia who are treated with ESAs according to the label are likely to experience a reduced need for transfusion and benefits in quality of life without the risk of adversely affecting survival. References 1 Ludwig H, Van Belle S, Barrett-Lee P et al. The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40: Littlewood TJ, Bajetta E, Nortier JW et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebocontrolled trial. J Clin Oncol 2001;19: Acknowledgment The author acknowledges the assistance of medical writer Julia O Regan, Bingham Mayne and Smith, Medical Communication. 7 Leyland-Jones B, Semiglazov V, Pawlicki M et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study. J Clin Oncol 2005;23: Randal J. FDA panel scrutinizes safety of anti-anemia drugs. J Natl Cancer Inst 2004;96:1061; doi: /jnci/ U.S. Food and Drug Administration. Oncologic Drugs Advisory Committee. May 4, Slides. Available at ac/04/slides/4037s2.htm. Accessed March 3, Bohlius J, Wilson J, Seidenfeld J et al. Recombinant human erythropoietins and cancer patients: Updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006;98: Shasha D, George MJ, Harrison LB. Once weekly dosing of epoetinalpha increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. Cancer 2003;98: Henke M, Laszig R, Rube C et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 2003;362: Henke M, Mattern D, Pepe M et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol 2006;24: U.S. Food and Drug Administration. Oncologic Drugs Advisory Committee. May 4, Briefing Information. Available at ohrms/dockets/ac/04/briefing/4037b2.htm. Accessed March 3, Bohlius J, Wilson J, Seidenfeld J et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 2006;3:CD Rose E, Rai K, Revicki D et al. Clinical and health status assessments in anemic chronic lymphocytic leukemia (CLL) patients treated with epoetin alfa (EPO). Blood 1994;84(suppl 1):526a. 13 Hearings before the SubCommittee on Oncologic Drugs Advisory Committee Research. P-174. May 4, Available at The Oncologist
6 Gascón 9 14 Case DC Jr, Bukowski RM, Carey RW et al. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst 1993;85: Henry DH, Brooks BJ Jr, Case DC Jr et al. Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy. Cancer J Sci Am 1995;1: Hearings Before the Subcommittee on Oncologic Drugs Advisory Committee Research, INT-1, May 4, Available at 17 Dammacco F, Castoldi G, Rödjer S. Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol 2001;113: Hearings Before the Subcommittee on Oncologic Drugs Advisory Committee Research, INT-3, May 4, Available at 19 Witzig TE, Silberstein PT, Loprinzi CL et al. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 2005;23: Hearings Before the Subcommittee on Oncologic Drugs Advisory Committee Research, N May 4, Available at 21 Leyland-Jones B; BEST Investigators and Study Group. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003;4: Vansteenkiste J, Pirker R, Massuti B et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94: Oberhoff C, Neri B, Amadori D et al. Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: A randomized, controlled study. Ann Oncol 1998;9: Blohmer JU, Wurschmidt F, Petry U et al. Results with sequential adjuvant chemo-radiotherapy with vs. without epoetin alfa for patients with highrisk cervical cancer: Results of a prospective, randomized, open and controlled AGO- and NOGGO-intergroup study. Ann Oncol 2004;15(suppl 3): Taylor K, Ganly P, Charu V. Randomized, double-blind, placebo-controlled study of darbepoetin alfa every 3 weeks for the treatment of chemotherapy-induced anemia. Blood 2005;106:Abstract Chang J, Couture F, Young S et al. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol 2005;23: Osterborg A, Brandberg Y, Hedenus M. Impact of epoetin-beta on survival of patients with lymphoproliferative malignancies: Long-term follow up of a large randomized study. Br J Haematol 2005;129: Savonije J, Van Groeningen C, Van Bochove A et al. Effects of early intervention with epoetin-alfa on transfusion requirement, hemoglobin level and survival during platinum-based chemotherapy: Results of a multicenter randomised controlled trial. Eur J Cancer 2005;41: Pronzato P, Cortesi E, van der Rijt C et al. Early intervention with epoetin alfa in breast cancer (BC) patients (pts) undergoing chemotherapy (CT): Results of a randomized, multicenter, phase IIIb study (EPO-INT- 47 Study Group). Ann Oncol 2002:13(suppl 5): Hedenus M, Adriansson M, San Miguel J et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: A randomized, double-blind, placebo-controlled study. Br J Haematol 2003;122: Kotasek D, Steger G, Faught W et al. Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy: Results of a double-blind, placebo-controlled, randomised study. Eur J Cancer 2003;39: Osterborg A, Boogaerts MA, Cimino R et al. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-hodgkin s lymphoma a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin s Lymphoma. Blood 1996;87: Coiffier B, Boogaerts M, Kainz C. Impact of epoetin beta versus standard care on quality of life in patients with malignant disease. Presented at the Sixth Congress of the European Haematology Association, Frankfurt, Germany, June 21 24, Grote T, Yeilding AL, Castillo R et al. Efficacy and safety analysis of epoetin alfa in patients with small-cell lung cancer: A randomized, doubleblind, placebo-controlled trial. J Clin Oncol 2005;23: ten Bokkel Huinink WW, de Swart CA, van Toorn DW et al. Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy. Med Oncol 1998;15: Thatcher N, De Campos ES, Bell DR et al. Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer. Br J Cancer 1999;80: Cazzola M, Messinger D, Battistel V et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-hodgkin s lymphoma: Dose finding and identification of predictors of response. Blood 1995;86: Wilkinson PM, Antonopoulos M, Lahousen M et al. Epoetin alfa in platinum-treated ovarian cancer patients: Results of a multinational, multicentre, randomised trial. Br J Cancer 2006;94: Aapro M, Barnadas A, Leonard RC et al. Effects of epoetin beta treatment in patients with metastatic breast cancer receiving chemotherapy. Results of the BRAVE trial. Presented at the 29th San Antonio Breast Cancer Symposium 2006, San Antonio, Texas, December 14-16, 2006.Available at: MaxHits=10&where%5B%5D=&andornot%5B%5D=&query=aapro. Accessed March 3, Moebus V, Lueck H, Thomssen C et al. The impact of epoetin-alpha on anemia, red blood cell (RBC) transfusions, and survival in breast cancer patients (pts) treated with dose-dense sequential chemotherapy: Mature results of an AGO phase III study (ETC trial). J Clin Oncol 2007;25(18 suppl):20s. 41 Hearings Before the Subcommittee on Oncologic Drugs Advisory Committee Research, EPO GBR-07; Available at 42 Del Mastro L, Venturini M, Lionetto R et al. Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapyinduced anemia. J Clin Oncol 1997;15: Bamias A, Aravantinos G, Kalofonos C et al. Prevention of anemia in patients with solid tumors receiving platinum-based chemotherapy by
7 10 Safety Update on ESAs recombinant human erythropoietin (rhuepo): A prospective, open label, randomized trial by the Hellenic Cooperative Oncology Group. Oncology 2003;64: Dunphy FR, Harrison BR, Dunleavy TL et al. Erythropoietin reduces anemia and transfusions: A randomized trial with or without erythropoietin during chemotherapy. Cancer 1999;86: Razzouk BI, Hockenberry M, Hinds PS et al. A double-blind, placebocontrolled study of once-weekly epoetin alfa in children with cancer undergoing myelosuppressive chemotherapy. J Clin Oncol 2004;22(14 suppl): O Shaughnessy J, Vukelja SJ, Holmes FA et al. Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy. Clin Breast Cancer 2005;5: Amgen Inc. Background Information for Oncologic Drug Advisory Committee meeting, May 10, Safety of Erythropoiesis-Stimulating Agents (ESAs) in Oncology. Submitted April 7, 2007 by Amgen Inc., Thousand Oaks, CA. 48 Wright JR, Ung YC, Julian JA et al. Randomized, double-blind, placebocontrolled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 2007;25: Cascinu S, Fedeli A, Del Ferro E et al. Recombinant human erythropoietin treatment in cisplatin-associated anemia: A randomized, double-blind trial with placebo. J Clin Oncol 1994;12: Kurz C, Marth C, Windbichler G et al. Erythropoietin treatment under polychemotherapy in patients with gynecologic malignancies: A prospective, randomized, double-blind placebo-controlled multicenter study. Gynecol Oncol 1997;65: The Oncologist
Venous Thromboembolic Events and Erythropoiesis-Stimulating Agents: An Update
Venous Thromboembolic Events and Erythropoiesis-Stimulating Agents: An Update Mario Dicato Hematology-Oncology Service, Luxembourg Medical Centre, Luxembourg Key Words. Erythropoiesis-stimulating agents
More informationSupplementary webappendix
Supplementary webappendix This webappendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Bohlius J, Schmidlin K, Brillant C, et
More informationBC Cancer Protocol Summary Guidelines for the Use of Erythropoiesis-Stimulating Agents (ESAs) in Patients with Cancer
BC Cancer Protocol Summary Guidelines for the Use of Erythropoiesis-Stimulating Agents (ESAs) in Patients with Cancer Protocol Code SCESA Tumour Group Physician Contact Pharmacist Contact Supportive Care
More informationMeta analysis in Drug Safety Assessment with a Focus on ESA s and Diabetes
Meta analysis in Drug Safety Assessment with a Focus on ESA s and Diabetes Jesse A. Berlin, ScD Johnson & Johnson Pharmaceutical Research and Development Seattle Clinical Trials Symposium 22 November 2010
More informationApril 12, Coverage of ESAs for Patients with Conditions Other than End-Stage Renal Disease
[ASH Comments to the Centers for Medicare and Medicaid Services on coverage for Erythropoiesis Stimulating Agents (ESAs) filed electronically on April 12, 2007] April 12, 2007 The American Society of Hematology
More informationOncologist. The. Symptom Management and Supportive Care
The Oncologist Symptom Management and Supportive Care The Effectiveness of Darbepoetin Alfa Administered Every 3 Weeks on Hematologic Outcomes and Quality of Life in Older Patients With Chemotherapy-Induced
More informationErythropoiesis-stimulating agents: benefits and risks in supportive care of cancer
BENEFITS AND RISKS OF ESAs IN CANCER MEDICAL ONCOLOGY Erythropoiesis-stimulating agents: benefits and risks in supportive care of cancer B.L. Melosky MD ABSTRACT Anemia, already common in cancer patients,
More informationErythropoiesis stimulationg agents: evidence for their use for the treatment of anemia in
Erythropoiesis stimulationg agents: evidence for their use for the treatment of anemia in thoracic tumors and MICU Dr Dipesh Maskey Senior Resident Dept of Pulmonary & CCM 14 th Oct 2011 Anemia and cancer
More informationErythropoiesis-stimulating agents in the management of cancer patients with anemia: a meta-analysis
Original Article Erythropoiesis-stimulating agents in the management of cancer patients with anemia: a meta-analysis Xiaomei Li 1,2, Zhi Yan 3, Dexiao Kong 2,4, Wen Zou 5, Jihua Wang 1, Dianshui Sun 1,
More informationAnemia related to cancer may be due to the cancer
CMAJ Benefits and harms of erythropoiesis-stimulating agents for related to cancer: a meta-analysis Marcello Tonelli MD SM, Brenda Hemmelgarn PhD MD, Tony Reiman MD SM, Braden Manns MD MSc, M. Neil Reaume
More informationOncologist. The. Symptom Management and Supportive Care
The Oncologist Symptom Management and Supportive Care A Randomized, Open-Label, Multicenter Trial of Immediate Versus Delayed Intervention with Darbepoetin Alfa for Chemotherapy-Induced Anemia VEENA CHARU,
More informationABSTRACT. Keywords: Chemotherapy induced anaemia, gastrointestinal cancers, India.
An Open Labeled Two Arm Study to Evaluate the Feasibility, Quality of Life, Safety and Efficacy of Darbepoetin as Compared to Erythropoietin Inpatients with Chemotherapy Induced Anemia in Patients with
More informationThe. JOHN GLASPY, a,e LAURENT DEGOS, b,e MARIO DICATO, c,e GEORGE D. DEMETRI d,e LEARNING OBJECTIVES ABSTRACT
The Oncologist Comparable Efficacy of Epoetin Alfa for Anemic Cancer Patients Receiving Platinum- and Nonplatinum-Based Chemotherapy: A Retrospective Subanalysis of Two Large, Community-Based Trials JOHN
More informationAnaemia & Cancer. John de Vos Consultant Haematologist RSCH
Anaemia & Cancer John de Vos Consultant Haematologist RSCH overview Definitions & setting the scene Causes Consequences Biology Treatment Personal approach Patient Clinical team Anaemia - Definition :
More informationThis article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and
This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and education use, including for instruction at the authors institution
More informationSymptom Management and Supportive Care
This material is protected by U.S. Copyright law. Unauthorized reproduction is prohibited. For reprints contact: Reprints@AlphaMedPress.com Symptom Management and Supportive Care Early Intervention with
More informationDarbepoetin alpha in the treatment of cancer chemotherapy-induced anemia
REVIEWS Darbepoetin alpha in the treatment of cancer chemotherapy-induced anemia Alberto Grossi 1 Francesca Balestri 2 Simone Santini 3 1 IstitutoLeonardo da Vinci Hematology, Florence, Italy; 2 Blood
More informationJune 12, Dear Dr. Phurrough:
June 12, 2007 Steve E. Phurrough, MD, MPA Director, Coverage and Analysis Group Centers for Medicare & Medicaid Services Mail Stop C1-09-06 7500 Security Boulevard Baltimore, MD 21244 Dear Dr. Phurrough:
More informationRecombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials
Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials Julia Bohlius, Kurt Schmidlin, Corinne Brillant, Guido Schwarzer, Sven Trelle,
More informationEffective Health Care
Number 3 Effective Health Care Comparative Effectiveness of Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment Executive Summary Background Anemia (deficiency of red blood
More informationClinical and Cost Effectiveness of Darbepoetin alfa in Cancer Treatment-induced Anaemia
Clinical and Cost Effectiveness of Darbepoetin alfa in Cancer Treatment-induced Anaemia 8 th November 2004 A report for the National Institute for Clinical Excellence prepared by Amgen Ltd. EXECUTIVE SUMMARY
More informationEpogen / Procrit. Epogen / Procrit (epoetin alfa) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.06 Section: Prescription Drugs Effective Date: April1, 2014 Subject: Epogen / Procrit Page: 1 of 7
More informationMHRA Public Assessment Report. Epoetins for the management of anaemia associated with cancer: risk of tumour progression and mortality.
MHRA Public Assessment Report Epoetins for the management of anaemia associated with cancer: risk of tumour progression and mortality November 2007 Executive summary 2 Introduction 5 Epoetins for treatment
More informationDarbepoetin alfa administration in patients with non-hodgkin lymphoma and chemotherapy-induced anemia receiving (±R)CHOP
Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2013 Darbepoetin alfa administration in patients with non-hodgkin lymphoma
More informationMedication Prior Authorization Form
Procrit, Aranesp and (Epoetin Alfa) Policy Number: 1043 Policy History Approve Date: 12/11/2015 Effective Date: 12/11/2015 Preauthorization All Plans Benefit plans vary in coverage and some plans may not
More informationProduct: Darbepoetin alfa Clinical Study Report: Date: 22 August 2007 Page 2 of 14145
Date: 22 ugust 2007 Page 2 of 14145 2. SYNOPSIS Name of Sponsor: mgen Inc., Thousand Oaks, C, US Name of Finished Product: ranesp Name of ctive Ingredient: Darbepoetin alfa Title of Study: Randomized,
More informationOncologist. The. Symptom Management and Supportive Care
The Oncologist Symptom Management and Supportive Care Prediction of the Responsiveness to Treatment with Erythropoiesis-Stimulating Factors: A Prospective Clinical Study in Patients with Solid Tumors TILMAN
More informationEpoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multicentre, randomised trial
British Journal of Cancer (2006) 94, 947 954 All rights reserved 0007 0920/06 $30.00 www.bjcancer.com Epoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multicentre,
More informationErythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data (Review)
Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data (Review) Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke
More informationExact Search Strings
Appendix A. Exact Search Strings Exact Search Strings MEDLINE searches refined (performed 3/11/2005) 1. Search ("Erythropoietin"[MeSH] OR "Erythropoietin, Recombinant"[MeSH] OR "Epoetin Alfa"[MeSH] OR
More informationEffects of Epoetin-α on Quality of Life of Cancer Patients with Solid Tumors Receiving Chemotherapy*
Effects of Epoetin-α on Quality of Life of Cancer Patients with Solid Tumors Receiving Chemotherapy* C. CHRISTODOULOU 1, U. DAFNI 2, G. ARAVANTINOS 3, A. KOUTRAS 4, E. SAMANTAS 3, M. KARINA 5, J. JANINIS
More informationManaging Anemia in the Cancer Patient: Old Problems, Future Solutions Michael S. Gordon. doi: /theoncologist
Managing Anemia in the Cancer Patient: Old Problems, Future Solutions Michael S. Gordon The Oncologist 2002, 7:331-341. doi: 10.1634/theoncologist.7-4-331 The online version of this article, along with
More informationRecombinant human erythropoietin in cancer-treatment related anaemia.
Recombinant human erythropoietin in cancer-treatment related anaemia. A submission to the NICE technology appraisal process on behalf of the Royal College of Physicians, Royal College of Radiologists,
More informationEpoetin Alfa in Cancer Patients: Evidence-Based Guidelines
954 Journal of Pain and Symptom Management Vol. 22 No. 5 November 2001 Review Article Epoetin Alfa in Cancer Patients: Evidence-Based Guidelines Robert Turner, MD, Peter Anglin, MD, Ronald Burkes, MD,
More informationAs cancer shifts from an inevitable death
CHEMOTHERAPY-INDUCED ANEMIA: TREATING IT AS A DISEASE, NOT JUST A CONDITION J. Michael Hayes, PharmD, RPh * ABSTRACT Anemia related to cancer treatment has multiple etiologies, including bleeding, marrow
More informationLee Schwartzberg 1*, Ronald Burkes 2, Barry Mirtsching 3, Timothy Rearden 4, Peter Silberstein 5, Lorrin Yee 6, Amy Inamoto 7, Tom Lillie 7.
RESEARCH ARTICLE Open Access Comparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a randomized,
More informationLiterature Scan: Erythropoiesis Stimulating Agents
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationFDA Drug Safety Communication: Erythropoiesis-Stimulating Agents (ES...
Page 1 of 5 Home> Drugs> Drug Safety and Availability> Postmarket Drug Safety Information for Patients and Providers Drugs FDA Drug Safety Communication: Erythropoiesis-Stimulating Agents (ESAs): Procrit,
More informationAranesp. Aranesp (darbepoetin alfa) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.01 Subject: Aranesp Page: 1 of 6 Last Review Date: September 15, 2017 Aranesp Description Aranesp
More informationThe presence and severity of anemia in patients with lung
ORIGINAL ARTICLE A Randomized Trial Comparing Immediate versus Delayed Treatment of Anemia with Once-Weekly Epoetin Alfa in Patients with Non-small Cell Lung Cancer Scheduled to Receive First-Line Chemotherapy
More informationScottish Medicines Consortium
Scottish Medicines Consortium epoetin theta, 1,000 IU/0.5mL, 2,000 IU/0.5mL, 3,000 IU/0.5mL, 4,000 IU/0.5mL, 5,000 IU/0.5mL, 10,000 IU/1mL, 20,000 IU/1mL, 30,000 IU/1mL solution for injection in pre filled
More informationUpdate on Chemotherapy- Induced Anemia and Neutropenia Therapies
Update on Chemotherapy- Induced Anemia and Neutropenia Therapies ASCO 2007: Update on Chemotherapy- Induced Anemia and Neutropenia Therapies Safety and efficacy of intravenous iron in patients with chemotherapyinduced
More informationUpdates in the Management of Anemia in Cancer. Taylor M. Ortiz, MD May 19, 2017
Updates in the Management of Anemia in Cancer Taylor M. Ortiz, MD May 19, 2017 Objectives Recall common causes of anemia in patients with cancer Understand risks/benefits of blood transfusion in patients
More informationAnemia is a common occurrence in cancer patients, resulting from
1072 Once-Weekly Dosing of Epoetin- Increases Hemoglobin and Improves Quality of Life in Anemic Cancer Patients Receiving Radiation Therapy Either Concomitantly or Sequentially with Chemotherapy Daniel
More informationMiriam Kimel, PhD, Nancy K. Leidy, PhD, Sally Mannix, BA, Julia Dixon, BS
Volume 11 Number 1 2008 VALUE IN HEALTH Does Epoetin Alfa Improve Health-Related Quality of Life in Chronically Ill Patients with Anemia? Summary of Trials of Cancer, HIV/AIDS, and Chronic Kidney Disease
More informationHMO: Medical (provider setting); Rx (out patient) PPO/CDHP: Rx
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Epogen, Procrit (epoetin alfa, injection) Commercial HMO/PPO/CDHP
More informationKey Words. Anemia Cancer Chemotherapy Economic Erythropoiesis-stimulating agents Transfusion
The Oncologist Symptom Management and Supportive Care Health Economic Evaluation of Treating Anemia in Cancer Patients Receiving Chemotherapy: A Study in Belgian Hospitals ERIK SPAEPEN, a NADIA DEMARTEAU,
More informationQuality-of-Life and Health Benefits of Early Treatment of Mild Anemia
1909 Quality-of-Life and Health Benefits of Early Treatment of Mild Anemia A Randomized Trial of Epoetin alfa in Patients Receiving Chemotherapy for Hematologic Malignancies David J. Straus, MD 1 Marcia
More informationJustus-Liebig-University of Giessen, Giessen, Germany. 1. Relate anemia to treatment outcome in a number of solid tumors.
The Oncologist rhuepo and Treatment Outcomes: the Clinical Experience CLIFFORD A. HUDIS, a SIMON VAN BELLE, b JOSE CHANG, c KARSTEN MUENSTEDT d a Memorial Sloan-Kettering Cancer Center, New York, New York,
More informationA New Dose-intense Epoetin Alfa Regimen Effective in Anemic Cancer Patients Receiving Chemotherapy: An Open-label, Non Randomized, Pilot Study
A New Dose-intense Epoetin Alfa Regimen Effective in Anemic Cancer Patients Receiving Chemotherapy: An Open-label, Non Randomized, Pilot Study DANIELE SANTINI 1, BRUNO VINCENZI 1, ANNALISA LA CESA 1, VLADIMIR
More informationErythropoiesis-Stimulating Agents
Erythropoiesis-Stimulating Agents Policy Number: 5.01.04 Last Review: 8/2017 Origination: 8/2015 Next Review: 8/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for
More informationPoint of view about new guidelines on ESAs (erythropoiesis-stimulating agents)
Point of view about new guidelines on ESAs (erythropoiesis-stimulating agents) L. Plawny Recent concerns about the safety of erythropoietin stimulating agents (ESAs) in cancer patients have led to a reformulation
More informationAETNA BETTER HEALTH Prior Authorization guideline for Erythropoiesis Stimulating Agents (ESA)
AETNA BETTER HEALTH Prior Authorization guideline for Erythropoiesis Stimulating Agents (ESA) Drugs Covered Procrit Epogen Aranesp Authorization guidelines For patients who meet all of the following: Does
More informationPractice and Costs of Red Blood Cell (RBC) Transfusion in an Oncological Unit
Practice and Costs of Red Blood Cell (RBC) Transfusion in an Oncological Unit JAN NORUM 1,2 and MARI-ANN N. MOEN 3 1 Department of Oncology, University Hospital of North Norway, Tromsø; 2 Institute of
More informationPREDICTION OF RESPONSE TO OPTIMIZE OUTCOME OF TREATMENT WITH ERYTHROPOIETIN. Yves Beguin
PREDICTION OF RESPONSE TO OPTIMIZE OUTCOME OF TREATMENT WITH ERYTHROPOIETIN Yves Beguin Senior Research Associate of the National Fund for Scientific Research (FNRS, Belgium). Department of Medicine, Division
More informationClinical Policy: Darbepoetin alfa (Aranesp) Reference Number: ERX.SPMN.13
Clinical Policy: (Aranesp) Reference Number: ERX.SPMN.13 Effective Date: 10/16 Last Review Date: 09/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationTechnology appraisal guidance Published: 26 November 2014 nice.org.uk/guidance/ta323
Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy Technology appraisal guidance Published: 26 November 2014 nice.org.uk/guidance/ta323
More informationdoi: /theoncologist
Treating Anemia of Cancer with Every-4-Week Darbepoetin Alfa: Final Efficacy and Safety Results from a Phase II, Randomized, Double-Blind, Placebo-Controlled Study David Gordon, Gwen Nichols, Ali Ben-Jacob,
More informationKey Words. Recombinant erythropoietin Cancer-associated anemia Children Childhood cancer
The Oncologist Pediatric Oncology The Role of Recombinant Erythropoietin in Childhood Cancer ANANTH GOURI SHANKAR Department of Paediatric and Adolescent Oncology, University College London Hospitals NHS
More informationNational Institute for Clinical Excellence. Cancer Treatment Induced Anaemia: Epoetin (alfa and beta) and Darbepoetin alfa.
National Institute for Clinical Excellence Cancer Treatment Induced Anaemia: Epoetin (alfa and beta) and Darbepoetin alfa Submission from: Breakthrough Breast Cancer CancerBACUP Leukaemia CARE 8 th November
More informationResponse Predicting Factors to Recombinant Human Erythropoietin in Cancer Patients Undergoing Platinum-Based Chemotherapy
2408 Response Predicting Factors to Recombinant Human Erythropoietin in Cancer Patients Undergoing Platinum-Based Chemotherapy Manolo González-Barón 1 Amdio Ordóñez 1 Rosa Franquesa 2 Manuel Constenla
More informationAdvances in gastric cancer: How to approach localised disease?
Advances in gastric cancer: How to approach localised disease? Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation
More informationOutcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia
Support Care Cancer (2012) 20:159 165 DOI 10.1007/s00520-010-1083-7 ORIGINAL ARTICLE Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia Chris L. Pashos &
More informationCorporate Medical Policy Erythropoiesis-Stimulating Agents (ESAs)
Corporate Medical Policy Erythropoiesis-Stimulating Agents (ESAs) File Name: Origination: Last CAP Review: Next CAP Review: Last Review: erythropoiesis_stimulating_agents_(esas) 8/2011 3/2018 3/2019 6/2018
More informationAgenti stimolanti l eritropoiesi (ESA): Esistono problematiche di distribuzione, interazione ed efficacia nell epoca delle terapie target?
Agenti stimolanti l eritropoiesi (ESA): Esistono problematiche di distribuzione, interazione ed efficacia nell epoca delle terapie target? Rosa Giuliani Oncologia Medica Ospedale S. Camillo-Forlanini ESA:
More informationErythropoiesis-Stimulating Agents (ESA s): epoetin alfa (Epogen and Procrit ), darbepoetin alfa (Aranesp ), and pegylated epoetin beta (Mircera )
Erythropoiesis-Stimulating Agents (ESA s): epoetin alfa (Epogen and Procrit ), darbepoetin alfa (Aranesp ), and pegylated epoetin beta (Mircera ) Applies to all products administered or underwritten by
More informationConversion Dosing Guide:
Conversion Dosing Guide: From epoetin alfa to Aranesp in patients with anemia due to CKD on dialysis Indication Aranesp (darbepoetin alfa) is indicated for the treatment of anemia due to chronic kidney
More informationClinical UM Guideline
Subject: Guideline #: Current Effective Date: 12/28/2016 Status: Reviewed Last Review Date: 11/03/2016 Description This document addresses recombinant, or man-made, erythropoietin products: Aranesp (Darbepoetin
More informationChronic anemia is a common complication of
Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cancer patients Trends in Hematology/Oncology review haematologica 2002; 87:1209-1221
More informationANEMIA DRUGS: DARBEPOETIN ALFA, EPOETIN ALFA, AND METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA
UnitedHealthcare Commercial Medical Benefit Drug Policy ANEMIA DRUGS: DARBEPOETIN ALFA, EPOETIN ALFA, AND METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA Policy Number: 2017D0028N Effective Date: October 1, 2017
More informationARANESP (darbepoetin alfa) injection, for intravenous or subcutaneous use Initial U.S. Approval: 2001
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ARANESP safely and effectively. See full prescribing information for ARANESP. ARANESP (darbepoetin
More informationANEMIA IN CANCER ROLE OF IV IRON
ANEMIA IN CANCER ROLE OF IV IRON IRON DEFICIENCY Absolute vs functional Absolute iron deficiency µ anemia = no iron stores : ferritin < 20 µg/l in N individual < 100 µg/l in infl/cancer patient Functional
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Darbepoetin Alfa (Aranesp) Reference Number: CP.PHAR.236 Effective Date: 06.01.16 Last Review Date: 05.18 Line of Business: HIM, Medicaid Coding Implications Revision Log See Important
More informationHospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain; c Center for Oncology and Hematology, Wilhelminen Hospital, Vienna, Austria
The Oncologist Anemia Management in Oncology and Hematology JERRY L. SPIVAK, a PERE GASCÓN, b HEINZ LUDWIG c a Johns Hopkins University, School of Medicine, Baltimore, Maryland, USA; b Medical Oncology,
More informationEpoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment: Comparative Effectiveness Update
Comparative Effectiveness Review Number 113 Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment: Comparative Effectiveness Update Comparative Effectiveness Review Number
More informationAcetaminophen recommendations from the Food and Drug Administration Advisory Committee
TABLE OF CONTENTS Acetaminophen: recommendations from the FDA Advisory Committee 1 Recombinant human erythropoiesis-stimulating agents and mortality in cancer patients Hospital-acquired pneumonia: risks
More informationIron Supplementation and Erythropoiesis-Stimulatory Agents in the Treatment of Cancer Anemia
Iron Supplementation and Erythropoiesis-Stimulatory Agents in the Treatment of Cancer Anemia Paolo Pedrazzoli, MD 1, Giovanni Rosti, MD 2, Simona Secondino, MD 1, and Salvatore Siena, MD 1 Unresponsiveness
More informationDrug Class Prior Authorization Criteria Erythropoiesis Stimulating Agents (ESAs)
Drug Class Prior Authorization Criteria Erythropoiesis Stimulating Agents (ESAs) Line of Business: Medicaid P & T Approval Date: May 16, 2018 Effective Date: July 1, 2018 This policy has been developed
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES PROCRIT METHOXY PEG-EPOETIN BETA MIRCERA 35005
Generic Brand HICL GCN Exception/Other DARBEPOETIN ALFA IN ARANESP 22890 POLYSORBATE EPOETIN ALFA EPOGEN, 04553 PROCRIT METHOXY PEG-EPOETIN BETA MIRCERA 35005 GUIDELINES FOR USE NOTE: Requirements regarding
More informationOriginal article. chemotherapy ranges from 9% to 40% [3]. Anemia related to platinum-containing chemotherapy
Annals of Oncology 9: 255-260. 1998. 1998 Kluwer Academic Publishers. Primed in the Netherlands. Original article Recombinant human erythropoietin in the treatment of chemotherapyinduced anemia and prevention
More informationoriginal article introduction original article
Annals of Oncology 22: 1999 2006, 2011 doi:10.1093/annonc/mdq713 Published online 7 March 2011 PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy
More informationErythropoiesis Stimulating Agents (ESA)
Erythropoiesis Stimulating Agents (ESA) Policy Number: Original Effective Date: MM.04.008 04/15/2007 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 06/01/2015 Section: Prescription
More informationRadiotherapy-Associated Anemia: The Scope of the Problem
Radiotherapy-Associated Anemia: The Scope of the Problem LOUIS B. HARRISON, DANIEL SHASHA, CAROL WHITE, BEVERLY RAMDEEN Department of Radiation Oncology, Beth Israel Medical Center, St. Luke s-roosevelt
More informationTreatment with erythropoiesis-stimulating agents in chronic kidney disease patients with cancer
mini review http://www.kidney-international.org & 2014 International Society of Nephrology Treatment with erythropoiesis-stimulating agents in chronic kidney disease patients with cancer Azzour D. Hazzan
More informationTrends in Anemia Management in Hemodialysis Patients with Cancer
American Journal of Nephrology Original Report: Patient-Oriented, Translational Research Received: March 16, 2015 Accepted: August 13, 2015 Published online: October 7, 2015 Trends in Anemia Management
More informationScholar Commons. University of South Carolina. Minghui Li University of South Carolina. Theses and Dissertations
University of South Carolina Scholar Commons Theses and Dissertations 2017 Impact of Medicare Reimbursement Policy Change on the Utilization, Risks, and Costs Associated with Erythropoiesis-Stimulating
More informationDepartment of Hematology, Uppsala University Hospital, Uppsala, Sweden
International Scholarly Research Network ISRN Hematology Volume 2011, Article ID 108397, 6 pages doi:10.5402/2011/108397 Review Article Effects of Iron Supplementation on Erythropoietic Response in Patients
More informationThe Role of Erythropoiesis-Stimulating Agents in the Treatment of Anemia
n report n The Role of Erythropoiesis-Stimulating Agents in the Treatment of Anemia Steven Fishbane, MD Correction of Anemia and Impact on Quality of Life Proper treatment of anemia can improve a patient
More informationCancer-related fatigue: clinical practice versus practice guidelines
Support Care Cancer (2011) 19:531 538 DOI 10.1007/s00520-010-0848-3 ORIGINAL ARTICLE Cancer-related fatigue: clinical practice versus practice guidelines Doranne L. Hilarius & Paul H. Kloeg & Elsken van
More informationWhat are cancer patients willing to pay for prophylactic epoetin alfa? A cost-benefit analysis Ortega A, Dranitsaris G, Puodziunas A L
What are cancer patients willing to pay for prophylactic epoetin alfa? A cost-benefit analysis Ortega A, Dranitsaris G, Puodziunas A L Record Status This is a critical abstract of an economic evaluation
More informationMonitor G-CSF Study Treatment patterns and outcomes in the prophylaxis of chemotherapy induced neutropenia with biosimilar filgrastim (Zarzio )
Monitor G-CSF Study Treatment patterns and outcomes in the prophylaxis of chemotherapy induced neutropenia with biosimilar filgrastim (Zarzio ) Heinz Ludwig Wilhelminen Cancer Research Institute c/o I
More informationIntroduction ORIGINAL ARTICLE. Mark Vincent George Dranitsaris Sunil Verma Cathy Lau Pere Gascon Simon Van Belle Heinz Ludwig
Support Care Cancer DOI 10.1007/s00520-006-0154-2 ORIGINAL ARTICLE Mark Vincent George Dranitsaris Sunil Verma Cathy Lau Pere Gascon Simon Van Belle Heinz Ludwig The development and validation of a prediction
More informationPROCRIT (epoetin alfa) for Injection
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PROCRIT safely and effectively. See full prescribing information for PROCRIT. PROCRIT (epoetin alfa)
More informationControversies in Transfusion Medicine
Controversies in Transfusion Medicine Jeffrey L. Carson, M.D. Richard C. Reynolds Professor of Medicine Chief, Division of General Internal Medicine Robert Wood Johnson Medical School New Brunswick, New
More informationPeer Review Report. [erythropoietin-stimulating agents]
21 st Expert Committee on Selection and Use of Essential Medicines Peer Review Report [erythropoietin-stimulating agents] (1) Does the application adequately address the issue of the public health need
More informationOncologist. The. Symptom Management and Supportive Care
The Oncologist Symptom Management and Supportive Care Effects of Aerobic Exercise Training in Anemic Cancer Patients Receiving Darbepoetin Alfa: A Randomized Controlled Trial KERRY S. COURNEYA, a LEE W.
More informationAnemia is a prevalent clinical issue among patients with cancer, occurring as
THERAPEUTIC OPTIONS FOR PATIENTS WITH CANCER AND TREATMENT-RELATED ANEMIA Brenda K. Shelton, MS, RN, CCRN, AOCN* ABSTRACT Anemia is a common clinical problem among patients with cancer, resulting from
More informationClinical Policy Title: Erythropoietin for end-stage renal disease
Clinical Policy Title: Erythropoietin for end-stage renal disease Clinical Policy Number: 00.02.07 Effective Date: June 1, 2015 Initial Review Date: February 19, 2014 Most Recent Review Date: January 18,
More informationAnaemia, Neutropenia, Thrombocytopenia, Hemostasis and Cancer
Madrid March 6-7 14 th ANNUAL COURSE 2015 Anaemia, Neutropenia, Thrombocytopenia, Hemostasis and Cancer Safety update on EPOs in chemotherapy treated cancer patients P. Gascon 1 What are we celebrating
More informationSwami Murugappan MD PhD Hematology Oncology Fellow University of Washington April 27, 2012
Swami Murugappan MD PhD Hematology Oncology Fellow University of Washington April 27, 2012 Outline Clinical indications of recombinant Erythrop0ietin (EPO) Concerns about the use of EPO in chronic kidney
More information